$DGX

KUPPUSAMY KARTHIK sold $1.6M of DGX

KUPPUSAMY KARTHIK (SVP, Clinical Solutions) sold 8,147 shares of QUEST DIAGNOSTICS INC (DGX) at $200.00 ($1.63M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KUPPUSAMY KARTHIK
Published Jun 8, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DGX
Neutral
medium confidence
Mentioned
$DGX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DGXNeutralLow
01

Why it matters

The newest concrete fact is the specific open-market sale size, price, and 10b5-1 status by a clinical solutions SVP; this can marginally influence sentiment but rarely drives fundamentals.

02

Market read

A $1.63M insider sale under 10b5-1 is a modest sentiment datapoint for DGX, with limited standalone trading impact.

03

What to watch

Traders should check whether DGX has concurrent fundamental catalysts (earnings, guidance, contract/regulatory updates) since Form 4 alone is usually low-signal.

Relevance 5/10Novelty 8/10Timing: Filed 2026-06-08; sale dated 2026-06-04

Background

The article is an SEC Form 4 insider transaction disclosure for Quest Diagnostics (DGX).

Company-level read

Ticker impact

$DGXNeutralMedium confidence
Context

Quest Diagnostics SVP Kuppusamy Karthik sold 8,147 shares (~$1.63M) in an open-market transaction under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless accompanied by other news.

Evidence & confidence

The filing is a disclosed sale (not a buy), but it is explicitly under a pre-arranged 10b5-1 plan, which typically reduces signal strength.

Market effects

Minimal; single-insider Form 4 selling does not reset sector fundamentals.

None indicated.

None indicated.

Counterpoint

Because the sale is on a 10b5-1 plan, it may reflect liquidity/tax planning rather than bearish expectations.

Key entities

  • Quest Diagnostics Inc.

    DGX, the company whose insider transaction was disclosed.

  • Kuppusamy Karthik

    SVP, Clinical Solutions; sold 8,147 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DGXMed

New York State Data Exposed Following Quest Diagnostic Breach

Quest Diagnostics disclosed a data breach in its Quanum Lab Services Manager system, exposing patient records, including names, Social Security numbers, and medical information. The breach was contained, but the exact number of affected individuals is still under investigation. Quest will notify impacted patients and offer identity theft monitoring services. The company serves 1 in 3 American adults annually.

$DGXMed

Quest Diagnostics says unauthorized access to lab-ordering system exposed patient records

Quest Diagnostics reported unauthorized access to its Quanum Lab Services Manager system, exposing patient records. The breach was discovered on Oct. 21, 2026, and disclosed the next day. The company is investigating with outside experts and has notified law enforcement. No disruption to customer operations was reported, and no threat group has claimed responsibility. Quest has temporarily paused access to affected systems and recommended alternative methods for orders and results.

$DGXLow

Medical Testing Giant Quest Diagnostics Confirms Massive Security Breach Exposing Sensitive Patient Records Amid a Coordinated Global Hacking Surge

Quest Diagnostics confirmed a security breach exposing patient records via its Quanum Lab Services Manager system. The breach, discovered on October 21, impacted protected health information and personal data. The company has taken steps to contain the breach, but the full extent of the damage is still under investigation. This incident is part of a broader surge in global cyberattacks, including a critical flaw in the PHP programming language.

$DGXMedAI 8/10

Quest Diagnostics Q3 2026 Revenue Rises to $3.1B, Diluted EPS Up to $2.78

Quest Diagnostics reported Q3 2026 revenue of $3.1B, up 10% YoY, with diluted EPS rising to $2.78. Operating income increased to $479M. Year-to-date revenue reached $9.035B, with net income attributable to Quest at $884M. The company maintained strong cash flow and returned capital through buybacks and dividends, but noted rising operating costs and debt.